SGLT2 inhibitors, a class of diabetes drugs, may reduce the risk of Alzheimer’s, vascular dementia, and Parkinson’s disease, according to a large study. Results showed a 20% to 30% lower risk for these conditions, though further research is needed for long-term validation. According to a study recently published in Neurology, the medical journal of the […]
Source link
